Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02853318
Title Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications

ovary epithelial cancer

fallopian tube cancer

peritoneum cancer

Therapies

Bevacizumab + Cyclophosphamide + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Roswell Park Cancer Institute Buffalo New York 14263 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field